
EU orders 100 million additional doses from Biontech
To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

BioPhero A/S raises US$17m in Series A funding
New investor exFMC Ventures, as well as existing investors Syngenta Group Ventures and Novo Holdings also participated in the...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

Media hype on Denmark’s decision to halt AZD1222 vaccination
Since Denmark suspended vaccination with AstraZeneca’s bashed Covid-19 vaccine, AZD1222 is facing questions over its safety. Denmark’s...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...